Omacetaxine mepesuccinate
- Generic Name
- Omacetaxine mepesuccinate
- Brand Names
- Synribo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39NO9
- CAS Number
- 26833-87-4
- Unique Ingredient Identifier
- 6FG8041S5B
- Background
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 200...
- Indication
Used in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
- Associated Conditions
- Refractory, accelerated phase Chronic myeloid leukemia, Refractory, chronic phase Chronic myeloid leukemia
- Associated Therapies
- -
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 60
- Registration Number
- NCT06744556
VHAG in Treating R/R T-ALL/LBL
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT06742463
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 81
- Registration Number
- NCT06361329
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 500
- Registration Number
- NCT06221683
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳XiangYa Hospital Central South University, Changsha, Hunan, China
🇨🇳Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Target Recruit Count
- 60
- Registration Number
- NCT05805098
- Locations
- 🇨🇳
Qiu Huiying, Suzhou, Jiangsu, China
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-05-06
- Target Recruit Count
- 20
- Registration Number
- NCT05805072
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Shanxi Bethune Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05726110
- Locations
- 🇨🇳
Tao Wang, Taiyuan, Shanxi, China
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT04874194
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
- Conditions
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Ge Zheng
- Target Recruit Count
- 100
- Registration Number
- NCT04248595
- Locations
- 🇨🇳
Department of Hematology, Zhongda Hospital, Medical School of Southeast University, NanJing, China
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
- Conditions
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT04126681
- Locations
- 🇨🇳
Nanfang hospital of southern medical university, Guangzhou, Guangdong, China
🇨🇳Union Hospital medical college Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine(hematology dept), Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.